Immuneering Corp(IMRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.03 | Insider Own | 14.02% | Shs Outstand | 64.7M | Perf Week | 6.68% |
| Market Cap | 0.26B | Forward P/E | - | EPS next Y | -12.26% | Insider Trans | 0.09% | Shs Float | 55.6M | Perf Month | -3.39% |
| Enterprise Value | 0.11B | PEG | - | EPS next Q | -0.31 | Inst Own | 55.14% | Short Float | 29.34% | Perf Quarter | -5.67% |
| Income | -0.06B | P/S | - | EPS this Y | 11.92% | Inst Trans | 12.17% | Short Ratio | 23.69 | Perf Half Y | -24% |
| Sales | 0.00B | P/B | 1.35 | EPS next 5Y | 3.7% | ROA | -47.31% | Short Interest | 16.32M | Perf YTD | -39.36% |
| Book/sh | 2.95 | P/C | 1.72 | EPS past 3/5Y | 12.72% -13.77% | ROE | -52.15% | 52W High | -52.95% ($8.48) | Perf Year | -38.52% |
| Cash/sh | 2.32 | P/FCF | - | Sales past 3/5Y | - | ROIC | -29.53% | 52W Low | 18.05% ($3.38) | Perf 3Y | -20.2% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 45.56% | Gross Margin | - | Volatility(W/M) | 5.47% 5.13% | Perf 5Y | -85.29% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.2 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 19.47 | EPS Q/Q | 33.46% | Profit Margin | - | RSI (14) | 51.82 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 19.47 | Sales Q/Q | - | SMA20 | 5.3% ($3.79) | Beta | 0.47 | Target Price | $17.17 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/6 | SMA50 | -8.05% ($4.34) | Rel Volume | 2.09 | Prev Close | $3.83 |
| Employees | 37 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | -0.52% - | SMA200 | -17.1% ($4.81) | Avg Volume(3M) | 0.69M | Price | $3.99 |
| IPO | 2021/7/30 | Option/Short | Yes/Yes | Trades | 7066 | Volume | 1,442,747 | Change | 4.18% |
🧬 This is a clinical-stage oncology biotech developing Deep Cyclic Inhibitors that intermittently block tumor signaling pathways. Its lead candidate, atebimetinib, has entered late-stage clinical trials for first-line metastatic pancreatic cancer, with the company focusing on a precision oncology-based novel drug pipeline.
Over the past 1 year, on the lower side
53% below its 1-year high.
Traded more than usual. That is 209% of its average volume.
IMRX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +11.9% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -85.3%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
29.3% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #280 of 594 in the industry
Based on market cap of $258M.
FAQ
What kind of company is IMRX?
IMRX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IMRX?
The market cap of IMRX is approximately $258M, ranking 3,811 within its sector.
What is the 52-week high and low for IMRX?
IMRX has recorded a 52-week high of $8.48 and a low of $3.38.
